U.S. market Closed. Opens in 16 hours 9 minutes

MTNB | Matinas BioPharma Holdings, Inc. Stock Overview

(Stock Exchange: AMEX)
Day's Range 0.5200 - 0.5674
52 Week Range 0.5050 - 21.50
Beta N/A
Implied Volatility N/A
IV Rank N/A
Day's Volume 176,809
Average Volume 103,531
Shares Outstanding 5,016,320
Market Cap 2,758,976
Sector Healthcare
Industry Biotechnology
IPO Date 2014-07-21
Valuation
Profitability
Growth
Health
P/E Ratio -0.10
Forward P/E Ratio N/A
EPS -5.50
1YR Price Target N/A
Dividend Yield N/A
Dividend Per Share N/A
Dividend ExDate N/A
Dividend PayDate N/A
Employees 32
Country USA
Website MTNB
Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates. It develops products using its lipid nanocrystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nano-crystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides. Its lead product candidate is LYPDISO, a prescription-only omega-3 free fatty acid-based composition intended for the treatment of cardiovascular and metabolic conditions. The company also offers MAT2203, an oral formulation of amphotericin B that is in Phase II clinical trials for the prevention of invasive fungal infections due to immunosuppressive therapy in patients. In addition, it provides MAT2501, an orally administered formulation of the broad-spectrum aminoglycoside antibiotic amikacin that has completed Phase I clinical trials to treat various types of multidrug-resistant bacteria, including non-tuberculous mycobacterium infections, as well as various multidrug-resistant gram negative and intracellular bacterial infections. Matinas BioPharma Holdings, Inc. has a research collaboration with the National Institute of Allergy and Infectious Diseases for the development of Gilead's antiviral remdesivir; and a feasibility collaboration with Genentech, Inc. for the development of oral formulations. The company was incorporated in 2013 and is based in Bedminster, New Jersey.
*Chart delayed
Analyzing fundamentals for MTNB we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is weak. For more detailed analysis please see MTNB Fundamentals page.

Watching at MTNB technicals we can see that long-term trend is bullish, the same as bullish middle-term trend, as well as bullish short-term trend. More technicals details can be found on MTNB Technicals page.
An error has occurred. This application may no longer respond until reloaded. Reload 🗙